Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Air pollution and Alzheimer disease phenotype deplete esterified proresolving lipid mediator reserves in the brain
Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein
Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein
View: Text | PDF
Research Article Aging Neuroscience

Air pollution and Alzheimer disease phenotype deplete esterified proresolving lipid mediator reserves in the brain

  • Text
  • PDF
Abstract

BACKGROUND Traffic-related air pollution (TRAP) is a risk factor for Alzheimer disease (AD), where unresolved brain inflammation has been linked to deficits in the levels of free lipid mediators that enable the resolution of inflammation. It is unknown whether these deficits are due to reductions in esterified lipid pools, the main source of free bioactive proresolving lipids in the brain, and whether they are related AD pathophysiology.METHODS This unknown was tested by measuring brain esterified lipid mediators and pathogenic markers of AD in TgF344-AD and WT male and female rats exposed to filtered air or TRAP for 14 months; it was also tested in human postmortem prefrontal cortex of individuals with or without AD.RESULTS Significant reductions in proresolving lipid mediators esterified to neutral lipids and/or phospholipids were seen in AD and TRAP-exposed female rats, where levels were associated with inflammation, synaptic loss, and impaired glucose metabolism. Lower esterified proresolving lipid mediator concentrations were associated with older age in prefrontal cortex of humans with AD compared with controls.CONCLUSION Impaired resolution in AD is due to depletion of esterified proresolving lipid pools that supply the brain with free bioactive mediators involved in inflammation resolution. TRAP exposure alters the same esterified resolution pathways, reflecting convergent mechanisms underlying AD.

Authors

Ameer Y. Taha, Qing Shen, Yurika Otoki, Nuanyi Liang, Kelley T. Patten, Anthony E. Valenzuela, Christopher D. Wallis, Douglas J. Rowland, Abhijit J. Chaudhari, Keith J. Bein, Anthony S. Wexler, Lee-Way Jin, Brittany N. Dugger, Danielle J. Harvey, Pamela J. Lein

×

Figure 2

Oxylipin concentrations in brain NL of 15-month-old WT or TgF344-AD (Tg) female rats exposed to FA or TRAP for 14 months.

Options: View larger image (or click on image) Download as PowerPoint
Oxylipin concentrations in brain NL of 15-month-old WT or TgF344-AD (Tg)...
Data are shown as mean ± SD of n = 7 WT-FA, n = 7 Tg-FA, n = 6 WT-TRAP, and n = 7 Tg-TRAP. Data were analyzed by 1-way ANOVA followed by Duncan’s post hoc test. Different-letter superscripts indicate that the means differed significantly from each other at P < 0.05. (A–E) DGLA-derived oxylipins (A), ALA-derived oxylipins (B), EPA-derived oxylipins (C), AA-derived oxylipins (D), and DHA-derived oxylipins (E). DiHETE, dihydroxyeicosatetraenoic acid; DiHETrE, dihydroxyeicosatrienoic acid; DiHOME, dihydroxyoctadecenoic acid; DiHDPA, dihydroxydocosapentaenoic acid; EpDPE, epoxydocosapentaenoic acid; EpETE, epoxyeicosatetraenoic acid; EpETrE, epoxyeicosatrienoic acid; EpOME, epoxyoctadecenoic acid; HDoHE, hydroxydocosahexaenoic acid; HEPE, hydroxyeicosapentaenoic acid; HETE, hydroxyeicosatetraenoic acid; HETrE, hydroxyeicosatrienoic acid; HODE, hydroxyoctadecadienoic acid; HOTrE, hydroxyoctadecatrienoic acid; oxo-ETE, oxo-eicosatetraenoic acid; oxo-ODE, oxo-octadecadienoic acid; TriHOME, trihydroxyoctadecenoic acid.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts